Blueprint has one approved drug and enhances Sanofi’s immunology portfolio

Sanofi

Source: © HJBC/Shutterstock

Sanofi has outlined a strategic goal to strengthen its existing therapy areas, including immunology, through acquisitions

As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint Medicines in a deal worth $9.1 billion (£6.7 billion) in cash, with an additional $400 million on offer in performance milestone payments.

Blueprint has one drug – Avaykyt (Avaykit in US, avapritinib) – which is approved in the US, Europe and elsewhere to treat gastrointestinal stromal tumours, as well as the rare immunological disease systemic mastocytosis. Blueprint reported 2024 sales of $479 million for the drug, with forecasts for significant growth.

The deal also brings Sanofi Blueprint’s pipeline of developmental drugs, including one in phase 2/3 clinical trials and earlier-stage projects.

As Business editor, Phillip's aim is to highlight to readers the exciting and innovative chemistry going on in the commercial sector, as well as keeping them abreast of trends and developments in the world of chemistry businesses.View full profile

More Phillip Broadwith

Topics